Drugs, Pregnancy & Lactation

Q&A with the FDA: Implementing the Pregnancy and Lactation Labeling Rule


 

Q: Does the FDA have any plans to address labeling for over-the-counter products in terms of their impact on pregnancy, lactation, and reproductive potential?

A: The PLLR does not apply to over-the-counter products. However, the agency is continually reviewing the safety of products used over the counter, including impacts on pregnancy, lactation, and reproductive potential.

Q: How does the FDA plan to assess over time the usefulness of the new labeling for prescribers and patients and make revisions?

A: The draft guidance was issued concurrently with PLLR. Based on the comments received from the public on the draft, as well as learning from the initial revisions of labeling, the guidance will be revised as needed. Guidance statements issued by FDA are regularly reviewed and revised as needed.

Dr. Whyte, a board-certified internist, is the director of Professional Affairs and Stakeholder Engagement at the FDA. Do you have other questions about the PLLR? Send them to obnews@frontlinemedcom.com.

Pages

Recommended Reading

CDC: Vaccines prevent millions of illnesses, but measles makes a return
MDedge Dermatology
Supreme Court: Companies can deny contraceptive coverage
MDedge Dermatology
Link between autoimmune therapy, preterm birth is largely due to confounding
MDedge Dermatology
VIDEO: Experts offer top tips for flu season 2014-2015
MDedge Dermatology
Second child tests positive for HIV infection after apparent viral remission
MDedge Dermatology
FDA issues new pregnancy/lactation drug label standards
MDedge Dermatology
Evaluating the impact of FDA’s pregnancy and lactation labeling rule
MDedge Dermatology
Worse melanoma outcomes found in pregnant women
MDedge Dermatology
Cosmetic procedures in pregnancy
MDedge Dermatology
Risk factors identified for gestational eczema
MDedge Dermatology

Related Articles